A Decade of Innovation

Within a decade, Sunovion has brought forward several new treatment options to address serious medical conditions that impact the lives of millions of people worldwide. The company’s track record has included making significant advancements in the treatment of serious medical conditions and partnering on educational and advocacy initiatives to empower people living with these conditions.

Our Medicines

APTIOM® (eslicarbazepine acetate) is indicated as:

  • Monotherapy in the management of partial-onset seizures in adult patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy.
  • Adjunctive therapy in the management of adults, and children above 6 years of age, with partial-onset seizures who are not satisfactorily controlled with conventional therapy.

Download APTIOM® Product Monograph PDF.

CLASTEON® (clodronate disodium) is indicated:

CTP® (citalopram hydrobromide) is indicated: the symptomatic relief of depressive illness.

Download CTP® Product Monograph PDF.

CUBICIN® (daptomycin for injection) is indicated for the following infections in adults:

  • Complicated skin and skin structure infections (cSSSI) caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillinresistant strains), Streptococcus pyogenes and Streptococcus agalactiae.
  • Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided Staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant strains.

Download CUBICIN® Product Monograph PDF.

KYNMOBI® (apomorphine hydrochloride) is indicated for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease.

Download KYNMOBI® Product Monograph PDF.

For more information, please visit:
www.kynmobi.ca

LATUDA® (lurasidone HCl) is indicated:

  • for the management of the manifestations of schizophrenia.
  • as monotherapy or as adjunctive therapy with lithium or valproate for the acute management of depressive episodes associated with bipolar I disorder.

Download LATUDA® Product Monograph PDF.

LUNESTA® (eszopiclone) tablets is indicated for the treatment of insomnia and has been shown to decrease sleep latency and improve sleep maintenance.

Download LUNESTA® Product Monograph PDF.

For more information, please visit:
www.lunesta.ca

TROSEC® (trospium chloride) is indicated for the treatment of overactive bladder with symptoms of urge or mixed urinary incontinence, urgency, and urinary frequency.

Download TROSEC® Product Monograph PDF.